Voyager Therapeutics
Update in progressVYGR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Voyager Therapeutics is a biotechnology company focused on human genetics to treat neurological diseases. Its pipeline includes VY1706, a tau-silencing gene therapy, and VY7523, an anti-tau antibody for Alzheimer’s disease. It also advances Huntington’s disease programs. Voyager offers TRACER, an AAV capsid discovery platform, and ALPL-VYGR-NeuroShuttle for another CNS target, plus selective small molecules for ALS and FTD-TDP-43. Founded 2013, Lexington, MA.
Company score
- Sentiment
- -0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.19
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Alfred W. Sandrock Jr., M.D., Ph.D.
- Founded2013
- Employees141
- Websitewww.voyagertherapeutics.com
Identifiers
- ISINUS92915B1061
- FIGIBBG005ZSY233
- LEI54930082S4XVR0ZWCC74
- CUSIP92915B102
- CIK0001640266